A retrospective case series hypereosinophilia during dupilumab treatment: Hypereosinophilia could be a pharmacogenetic biomarker of dupilumab

Dermatol Ther. 2020 Nov;33(6):e13847. doi: 10.1111/dth.13847. Epub 2020 Jul 29.

Authors

Jiyoung Ahn¹, Joo Yoon Bae¹, Seong Jun Seo²

Affiliations

¹ Department of Dermatology, National Medical Center, Seoul, South Korea.
² Department of Dermatology, Chung-Ang University Hospital, Seoul, South Korea.

PMID: 32544266
DOI: 10.1111/dth.13847

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized* / adverse effects
Biomarkers
Eosinophilia* / chemically induced
Humans
Pharmacogenetics*
Retrospective Studies

Substances

Antibodies, Monoclonal, Humanized
Biomarkers
dupilumab